Biomarkers of bone metabolism in [²²³Ra] RaCl₂ therapy - association with extent of disease and prediction of overall survival.

ABSTRACT:

Background

The alpha-emitting radionuclide therapy [²²³Ra]RaCl₂ (Radium-223) improves overall survival (OS) and time to symptomatic skeletal event (SSE) in patients with metastatic castration-resistant prostate cancer (mCRPC). Evidence suggests that the effect of Radium-223 is partly exerted through an impact on the surrounding bone matrix. We hypothesized that bone metabolism markers (BMM) could provide predictive information regarding response to Radium-223. Accordingly, the aim of this study was to investigate changes in BMM during Radium-223 therapy and evaluate association with clinical outcome.

Methods

Prospective study of BMM in patients with mCRPC receiving Radium-223. Blood samples were collected before each administration of Radium-223 and the

SUBMITTER: Fosbol MO 

PROVIDER: S-EPMC11450107 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature